RCM
ORKA

Rotella Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Rotella Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-8
Closed -$24K – 417
2014
Q1 		$24K Buy
+8
New +$23.4K 0.03% 227

Other funds holding ORKA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rotella Capital Management's ORKA Position: Q2 2014 in Review

Rotella Capital Management sold out of Oruka Therapeutics (ORKA) in Q2 2014, closing a stake of 8 shares — an estimated $24K sold.

Rotella Capital Management first reported a position in ORKA in Q1 2014 and held it in 1 quarter. The position peaked at $24K in Q1 2014. 14 funds tracked by Wall St. Rank hold ORKA as of Q2 2014.

  • Rotella Capital Management reported no remaining Oruka Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Rotella Capital Management sold 8 Oruka Therapeutics shares in Q2 2014, an estimated $24K.
  • Rotella Capital Management first reported a position in Oruka Therapeutics in Q1 2014 and held it in 1 quarter.
  • Rotella Capital Management's Oruka Therapeutics position peaked at $24K in Q1 2014.
  • 14 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2014.

Based on Rotella Capital Management's 13F filing for Q2 2014, filed 18 Aug 2014.